Greenwich Life Sciences at Life

Greenwich Life Sciences. Gp2 is derived from the her2/neu protein, which is expressed in a variety of common cancers, including breast cancer. Gp2 is administered in combination.

Glsi) is a public biopharmaceutical company based in the houston, tx area that is developing gp2, a novel peptide immunotherapy, and is planning to commence a phase iii clinical trial. Greenwich lifesciences is currently preparing the cgmp manufacturing of gp2, selecting clinical trial partners, and finalizing a protocol towards commencing a phase iii clinical trial. Her2/neu is a cell surface receptor protein that is expressed in 75% of breast cancer in addition to a variety of other common cancers.

A dispatch from my sabbatical … Department of Economics Blog

Tumors with elevated expression of her2/neu protein are highly aggressive, resulting in an. Gp2 is administered in combination. Glsi) is a public biopharmaceutical company based in the houston, tx area that is developing gp2, a novel peptide immunotherapy, and is planning to commence a phase iii clinical trial. Greenwich lifesciences glsi focus on breast cancer immunotherapy.